Evidence map›Paper›PMID 37333140›Full record

ArticlebioRxiv : the preprint server for biology2023

Structural insight into CD93 recognition by IGFBP7.

Yueming Xu, Yi Sun, Yuwen Zhu, Gaojie Song

Open access · greenAbstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 2 countries.

Yueming XuORCID 0000-0002-9300-9703
Yi Sun
Yuwen Zhu
Gaojie SongORCID 0000-0002-7787-6452
East China Normal University · CNUniversity of Colorado Anschutz Medical Campus · US

Funding

The CD93 pathway and melanoma therapyR01CA258302 · NCI · UNIVERSITY OF COLORADO DENVER · PI Yuwen Zhu · 2022 to 2026
$1.8M
Melanoma Immunotherapy with GPR182 blockadeR01CA269644 · NCI · UNIVERSITY OF COLORADO DENVER · PI Yuwen Zhu · 2023 to 2026
$1.4M
The GPR171 pathway in cancer immunotherapyR01CA279398 · NCI · UNIVERSITY OF COLORADO DENVER · PI Yuwen Zhu · 2023 to 2026
$1.4M
NCI NIH HHS R01 CA258302NCI NIH HHS R01 CA269644NCI NIH HHS R01 CA279398
6 · The paper itself

Abstract

The CD93/IGFBP7 axis are key factors expressed in endothelial cells (EC) that mediate EC angiogenesis and migration. Upregulation of them contributes to tumor vascular abnormality and blockade of this interaction promotes a favorable tumor microenvironment for therapeutic interventions. However, how these two proteins associated to each other remains unclear. In this study, we solved the human CD93-IGFBP7 complex structure to elucidate the interaction between the EGF

Identifiers

PMID37333140
PMCPMC10274810
OpenAlexW4380090553

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.